Diagnosis and treatment of persons with acute thallium poisoning.

Acute poisoning Antidote therapy Extracorporeal detoxification Mass poisoning Neurotoxicity Thallium

Journal

Toxicology reports
ISSN: 2214-7500
Titre abrégé: Toxicol Rep
Pays: Ireland
ID NLM: 101630272

Informations de publication

Date de publication:
2021
Historique:
received: 25 12 2020
revised: 19 01 2021
accepted: 20 01 2021
entrez: 8 2 2021
pubmed: 9 2 2021
medline: 9 2 2021
Statut: epublish

Résumé

This study aimed to describe organs and systems damages in persons after mass poisoning with thallium and show the results of treatment. Forty-four persons (12 males and 32 females) with acute oral thallium poisoning were tested for thallium levels in blood and urine and examined by a toxicologist and a neurologist, and in some -cases, by a gynecologist, an ophthalmologist, and a psychiatrist. Persons were divided into the following three groups depending on the severity of the poisoning: I: This group consisted of 9 persons (blood thallium level 8.3-26.7 μg/L) and treatment applied in the hospital included intestinal lavage, antidote therapy with potassium-ferric hexacyanoferrate, sodium dimercaptopropanesulfonate; II: This group consisted of 21 persons (0.3-6.1 μg/L) who received a similar treatment at home; and III: This group consisted of 14 (normal) persons who did not receive any treatment. The most common combination of several symptoms such as alopecia (on day 17-23), muscle pain of different localization in the debut of the disease (>88.9 % of the persons), sudden unexplained general weakness (>76.2 % of the persons), peripheral paraparesis or tetraparesis (including no complaints), polyneuropathy (88.89 % in group I vs. 54.14 % in group II, p < 0.05), static and dynamic ataxia (33.3 % in group I vs. 19.4 % in group II, p < 0.05), vertigo (1/3 of the persons), postural tremor (1/3 of the persons), and cognitive and emotional disorders (2/3 of the persons). Ovarian dysfunction was observed in all women of group I but in 42.9 % of group II, p < 0.05. The treatment was successful. In group I, plasma and urine thallium level significantly decreased by 69.3 % and 84 %, respectively. Pain, movement and coordination disorders regressed first while tremor, sensory, cognitive and emotional disorders lasted longer. Polyneuropathies later became mononeuropathies. Tremor could increase despite a decreased thallium concentration. The Sklifosovsky Institute conducted the largest study in Russian Federation investigating disorders in persons with acute thallium poisoning confirmed by laboratory tests. The clinical symptoms were consistent with those reported in the literature. The applied treatment was successful and led to better results compared to our previous approaches of treating mass thallium poisoning. This study shows a typical combination of thallium poisoning symptoms and allows us to recommend a complex therapy without the use of extracorporeal detoxification methods.

Identifiants

pubmed: 33552926
doi: 10.1016/j.toxrep.2021.01.013
pii: S2214-7500(21)00013-5
pmc: PMC7848287
doi:

Types de publication

Journal Article

Langues

eng

Pagination

277-281

Informations de copyright

© 2021 Published by Elsevier B.V.

Déclaration de conflit d'intérêts

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Références

Drug Saf. 1990 Sep-Oct;5(5):384-9
pubmed: 2222870
Neuropathol Appl Neurobiol. 1991 Feb;17(1):3-9
pubmed: 2057049
J Clin Diagn Res. 2017 Apr;11(4):OD01-OD02
pubmed: 28571191
Neurotoxicology. 2006 Mar;27(2):291-5
pubmed: 16337004
J Assoc Physicians India. 2006 Jan;54:53-5
pubmed: 16649741
Toxicol Rev. 2003;22(1):29-40
pubmed: 14579545
Drug Chem Toxicol. 2013 Jul;36(3):369-83
pubmed: 22970858
J Med Toxicol. 2013 Mar;9(1):75-8
pubmed: 22865288
J Med Toxicol. 2011 Dec;7(4):306-11
pubmed: 21735311
Toxicol Lett. 1998 Sep 30;99(1):1-13
pubmed: 9801025
Arh Hig Rada Toksikol. 2010 Mar;61(1):111-9
pubmed: 20338874
Postgrad Med J. 2003 Feb;79(928):103-5
pubmed: 12612328
Vet Hum Toxicol. 1983 Feb;25(1):16-22
pubmed: 6338655
Adv Neurobiol. 2017;18:345-353
pubmed: 28889276

Auteurs

Lesya B Zavaliy (LB)

N.V. Sklifosovsky Research Institute for Emergency Medicine of the Department of Health of Moscow, 3 Bolshaya Sukharevskaya sq., Moscow, 129090, Russian Federation.

Sergey S Petrikov (SS)

N.V. Sklifosovsky Research Institute for Emergency Medicine of the Department of Health of Moscow, 3 Bolshaya Sukharevskaya sq., Moscow, 129090, Russian Federation.
A.I. Evdokimov Moscow State University of Medicine and Dentistry of the Ministry of Health of the Russian Federation, 20 Delegatskaya str., bldg. 1, Moscow, 1127473, Russian Federation.

Anastasia Yu Simonova (AY)

N.V. Sklifosovsky Research Institute for Emergency Medicine of the Department of Health of Moscow, 3 Bolshaya Sukharevskaya sq., Moscow, 129090, Russian Federation.
Scientific and Practical Toxicological Center of FMBA of Russia, 5 Bolshaya Sukharevskaya sq., Moscow, 129090, Russian Federation.

Mikhail M Potskhveriya (MM)

N.V. Sklifosovsky Research Institute for Emergency Medicine of the Department of Health of Moscow, 3 Bolshaya Sukharevskaya sq., Moscow, 129090, Russian Federation.
Scientific and Practical Toxicological Center of FMBA of Russia, 5 Bolshaya Sukharevskaya sq., Moscow, 129090, Russian Federation.

Fahimehsadat Zaker (F)

RASTA Research Institute, West Azerbaijan Technology Park (WASTP), 5756115322, Urmia, Iran.

Yuri N Ostapenko (YN)

N.V. Sklifosovsky Research Institute for Emergency Medicine of the Department of Health of Moscow, 3 Bolshaya Sukharevskaya sq., Moscow, 129090, Russian Federation.
Scientific and Practical Toxicological Center of FMBA of Russia, 5 Bolshaya Sukharevskaya sq., Moscow, 129090, Russian Federation.

Kapitalina K Ilyashenko (KK)

N.V. Sklifosovsky Research Institute for Emergency Medicine of the Department of Health of Moscow, 3 Bolshaya Sukharevskaya sq., Moscow, 129090, Russian Federation.
Scientific and Practical Toxicological Center of FMBA of Russia, 5 Bolshaya Sukharevskaya sq., Moscow, 129090, Russian Federation.

Tatyana I Dikaya (TI)

N.V. Sklifosovsky Research Institute for Emergency Medicine of the Department of Health of Moscow, 3 Bolshaya Sukharevskaya sq., Moscow, 129090, Russian Federation.

Olga B Shakhova (OB)

N.V. Sklifosovsky Research Institute for Emergency Medicine of the Department of Health of Moscow, 3 Bolshaya Sukharevskaya sq., Moscow, 129090, Russian Federation.

Anatoly K Evseev (AK)

N.V. Sklifosovsky Research Institute for Emergency Medicine of the Department of Health of Moscow, 3 Bolshaya Sukharevskaya sq., Moscow, 129090, Russian Federation.

Ramin Rezaee (R)

Clinical Research Unit, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
Neurogenic Inflammation Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.

Irina V Goroncharovskaya (IV)

N.V. Sklifosovsky Research Institute for Emergency Medicine of the Department of Health of Moscow, 3 Bolshaya Sukharevskaya sq., Moscow, 129090, Russian Federation.

Classifications MeSH